Career history of Stacey L. Jurchison
Former positions of Stacey L. Jurchison
| Companies | Position | Start | End |
|---|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Contact | 31/05/2019 | - |
| Public Communications Contact | 31/05/2019 | 31/03/2022 | |
| ALTIMMUNE, INC. | Investor Relations Contact | - | - |
| REXAHN PHARMACEUTICALS, INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - | |
| APTEVO THERAPEUTICS INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - | |
PharmAthene, Inc.
 PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Investor Relations Contact | - | - |
Statistics
International
| United States | 6 |
Operational
| Investor Relations Contact | 5 |
| Public Communications Contact | 3 |
Sectoral
| Health Technology | 6 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| APTEVO THERAPEUTICS INC. | Health Technology |
| ALTIMMUNE, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Private companies | 2 |
|---|---|
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Health Technology |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Stacey L. Jurchison
- Experience
